Nidufexor( LMB763 | LMB-763 )

Catalog No. M12669 CAS No. 1773489-72-7

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Nidufexor
Note

Research use only, not for human use.
Brief Description

Nidufexor (LMB763, LMB-763) is a novel potent farnesoid X receptor (FXR) agonist for the treatment of non-alcoholic steatohepatitis (NASH) and hepatobiliary disorders.
Description

Nidufexor (LMB763, LMB-763) is a novel potent farnesoid X receptor (FXR) agonist for the treatment of non-alcoholic steatohepatitis (NASH) and hepatobiliary disorders.
In Vitro

——
In Vivo

Animal Model:Han-Wistar rats Dosage:0.1, 0.3, 1.5, 7.5, 25, 100 mg/kg (Pharmacokinetic Analysis) Administration:Oral gavage, once daily for 14 days Result:On day 1 and 13, serum exposure increased approximately dose-proportionally from 0.1 to 100 mg/kg. Exposure at 0.1 and 0.3 mg/kg was likely underestimated on day 13. No significant accumulation was observed.
Synonyms

LMB763 | LMB-763
Pathway

Metabolic Enzyme/Protease
Target

FXR
Recptor

FXR
Research Area

——
Indication

——

CAS Number

1773489-72-7
Formula Weight

487.94
Molecular Formula

C27H22ClN3O4
Purity

>98% (HPLC)
Solubility

DMSO : 83.33 mg/mL 170.78 mM; H2O : < 0.1 mg/mL
SMILES

O=C(O)C1=CC=C(CN(CC2=CC=CC=C2)C(C3=NN(C)C4=C3COC5=CC=C(Cl)C=C54)=O)C=C1
Chemical Name

4-[(N-benzyl-8-chloro-1-methyl-1,4-dihydro[1]benzopyrano[4,3-c]pyrazole-3-carboxamido)methyl]benzoic acid